1,3-substituted cycloalkyl derivatives having acidic, mostly...

Details 1,3-substituted cycloalkyl derivatives having acidic, mostly... 1,3-substituted cycloalkyl derivatives having acidic, mostly...

2007-07-10

2011-11-01

McKane, Joseph (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S225000, C548S235000, C514S376000

Reexamination Certificate

active

08048901

ABSTRACT:
The invention relates to 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups and to their physiologically acceptable salts and physiologically functional derivatives.What is described are compounds of the formula I,in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved.

REFERENCES:
patent: 3174901 (1965-03-01), Sterne
patent: 5190923 (1993-03-01), Vincent et al.
patent: 5814647 (1998-09-01), Urban et al.
patent: 6221633 (2001-04-01), Ertl et al.
patent: 6221897 (2001-04-01), Frick et al.
patent: 6245744 (2001-06-01), Baringhaus et al.
patent: 6277831 (2001-08-01), Frick et al.
patent: 6342512 (2002-01-01), Kirsch et al.
patent: 6441022 (2002-08-01), Baringhaus et al.
patent: 6506778 (2003-01-01), Defossa et al.
patent: 6552048 (2003-04-01), Kirsch et al.
patent: 6566340 (2003-05-01), Frick et al.
patent: 6569835 (2003-05-01), Frick et al.
patent: 6624185 (2003-09-01), Glombik et al.
patent: 6642269 (2003-11-01), Frick et al.
patent: 6884812 (2005-04-01), Glombik et al.
patent: 6897198 (2005-05-01), Baringhaus et al.
patent: 7148246 (2006-12-01), Gretzke et al.
patent: 7399777 (2008-07-01), Glombik et al.
patent: 2004/0087648 (2004-05-01), Frick et al.
patent: 0462884 (1991-06-01), None
patent: WO 94/18183 (1994-08-01), None
patent: WO 94/18184 (1994-08-01), None
patent: WO 96/38428 (1996-12-01), None
patent: WO 97/26265 (1997-07-01), None
patent: 9728149 (1997-08-01), None
patent: 9741097 (1997-11-01), None
patent: WO 97/41097 (1997-11-01), None
patent: 9808871 (1998-03-01), None
patent: WO 98/08871 (1998-03-01), None
patent: WO 98/19998 (1998-05-01), None
patent: 9903861 (1999-01-01), None
patent: WO 99/03861 (1999-01-01), None
patent: 9915525 (1999-04-01), None
patent: WO 99/15525 (1999-04-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/62871 (1999-12-01), None
patent: WO 99/62872 (1999-12-01), None
patent: WO 99/67278 (1999-12-01), None
patent: WO 99/67279 (1999-12-01), None
patent: WO 00/40569 (2000-07-01), None
patent: WO 00/63208 (2000-10-01), None
patent: WO 00/64876 (2000-11-01), None
patent: WO 00/64888 (2000-11-01), None
patent: WO 00/66585 (2000-11-01), None
patent: WO 00/71549 (2000-11-01), None
patent: WO 00/78312 (2000-12-01), None
patent: WO 01/04146 (2001-01-01), None
patent: WO 01/09111 (2001-02-01), None
patent: WO 01/21602 (2001-03-01), None
patent: WO-01/21602 (2001-03-01), None
patent: WO 01/40169 (2001-06-01), None
patent: WO 01/40171 (2001-06-01), None
patent: WO 01/72290 (2001-10-01), None
patent: WO 01/81327 (2001-11-01), None
patent: WO 01/83451 (2001-11-01), None
patent: WO 01/85695 (2001-11-01), None
patent: WO 01/91752 (2001-12-01), None
patent: 0218355 (2002-03-01), None
patent: WO 02/30895 (2002-04-01), None
patent: WO 02/38541 (2002-05-01), None
patent: WO 02/50027 (2002-06-01), None
patent: WO 02/096864 (2002-12-01), None
patent: WO 02/100403 (2002-12-01), None
patent: 03011819 (2003-02-01), None
patent: WO 03/020269 (2003-03-01), None
patent: 03072102 (2003-04-01), None
patent: WO 03/040174 (2003-05-01), None
patent: WO 03/043985 (2003-05-01), None
patent: WO 03/084922 (2003-10-01), None
patent: WO 03/084923 (2003-10-01), None
patent: WO 03/104188 (2003-12-01), None
Asakawa, A. et. al., Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism Anxiety and Gastric Emptying in Mice, Hormone and Metabolic Reserch; vol. 33(9); 2001; pp. 554-558.
Berger, J., et. al., The Mechanisms of Action of PPARs, Annul. Rev. Med.; vol. 53; 2002; pp. 409-435.
Fruchart, J.C., et. al., PPARs, Metabolic Disease and Atherosclerosis, Pharmacological Research; vol. 44, No. 5; 2001 pp. 345-352.
Kersten, S., et. al., Roles of PPARs in Health and Disease, Nature; vol. 405; May 25, 2000; pp. 421-424.
Kliewer, S.A., et. al., Peroxisome Proliferator-Activated Receptors: From Genes to Physiology, Recent Prog. Horm Res.; vol. 56; 2001; pp. 239-263.
Lee, D.W., et. al., Leptin agonists as a potential approach to the treatment of obesity, Drugs of the Future; vol. 26(9); 2001; pp. 873-881.
Motojima, K., et. al., Peroxisome Proliferator-Activated Receptor (PPAR): Structure, Mechanisms of Activation and Diverse Functions, Cell Structure and Function; vol. 18; 1993; pp. 267-277.
Okada, H., et. al., Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas, Chem. Pharm. Bull.; vol. 42(1); 1994; pp. 57-61.
Pineda Torra, I., et. al., Peroxisome Proliferator-activated Receptors: from Transcriptional Control to Clinical Practice, Curr. Opin. Lipidol; vol. 12; 2001; pp. 245-254.
Pineda Torra, I., et. al., Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging, Curr. Opin. Lipidol; vol. 10; 1999; pp. 151-159.
Vidal-Puig, A., et. al., Regulation of PPAR y Gene Expression by Nutrition and Obesity in Rodents, J. Clin. Invest.; vol. 97, No. 11, 1996; pp. 2553-2561.
Wilson, T.M., et. al., The PPARs: From Orphan Receptors to Drug Discovery, Journal of Medicinal Chemistry; vol. 43, No. 4; 2000; pp. 527-550.
Zunft, H.J.F., et. al., Carob Pulp Preparation for Treatment of Hypercholesterolemia, Advances in Natural Therapy; vol. 18, No. 5; Sep.-Oct. 2001; pp. 230-236.
Amri E. et al., “Cloning of a Protein That Mediates Transcriptional Effects of Fatty Acids in Preadipocytes”, The Journal of Biological Chemistry, 270(5):2367-2371 (Feb. 1995).
Beck F. et al., “The ontogeny of perosisome-proliferator-activated receptor gene expression in the mouse and rat”, Proc. R. Soc. Lond. B. 247:83-87 (1992).
Colville-Nash P. et al., “Inhibition of Inducible Nitric Oxide Synthase by Peroxisome Proliferator-Activated Receptor Agonists: Correlation with Induction of Heme Oxygenase 1”, The Journal of Immunology, 161:978-984 (1998).
De Faire U. et al., “Retardation of Coronary Atherosclerosis: The Bezafibrate Coronary Atherosclerosis intervention Trial (BECAIT) and Other Angiographic Trials”, Cardiovasc Drugs Ther, 11:257-263 (1997)..
Demetri G. et al., “Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma”, Proc. Natl. Acad. Sci. USA, 96:3951-3956 (Mar. 1999).
Dunaif A. et al., “The Insulin-Sensitizing Agent Troglitazone Improves Metabolic and Reproductive Abnormalities in the Polycystic Ovary Snydrome”, Journal of Clinical Endocrinology of Metabolism, 81(9):3299-3306 (1996).
Elbrecht A. et al., “Molecular Cloning, Expression and Characterization of Human Peroxisome Proliferator Activated Receptors γ1 and γ2”, Biochemical arid Biophysical Research Communications, 224:431-437 (1996).
Elstner E. et al., “Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice”, Proc. Nati. Acad. Sci, USA, 95:8806-8811 (Jul. 1998).
Forman B. et al. “15-Deoxy-Delta 12, 14-Prostaglandin J2 is a Ligand for the Adipocyte Determination Factor PPARγ”, Cell, 83:803-812 (Dec. 1, 1995).
Frick M. et al. “Prevention of the Angiographic Progression of Coronary and Vein-Graft Atherosclerosis by Gemifibrozil After Coronary Bypass Surgery in Men with Low Levels of HDL Cholesterol”, Circulation, 96:2137-2134 91997).
Göttlicher M. et al., “Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocoritcoid receptor”, Proc. Natl. Acad. Sci. USA, 89:4653-4657 (May 1992).
Green S. “Receptor-Mediated Mechanisms of Peroxisome Proliferators”, Biochemical Pharmacology, 43(3):393-401 (1992).
Horikoshi H. et al., “Troglitazone—a novel antidiabetic drug for treating insulin resistance”, DDT, 3(2):79-88 (Feb. (1998).
Lehmann J. et al.,

Affiliated with

Also associated with

Rating

1,3-substituted cycloalkyl derivatives having acidic, mostly... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 1,3-substituted cycloalkyl derivatives having acidic, mostly..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,3-substituted cycloalkyl derivatives having acidic, mostly... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4305643